Market Cap 7.24B
Revenue (ttm) 4.05B
Net Income (ttm) 22.20M
EPS (ttm) N/A
PE Ratio 14.19
Forward PE 15.33
Profit Margin 0.55%
Debt to Equity Ratio 0.78
Volume 823,800
Avg Vol 1,554,620
Day's Range N/A - N/A
Shares Out 49.12M
Stochastic %K 47%
Beta 1.48
Analysts Sell
Price Target $158.64

Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of serv...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 781 222 6000
Address:
251 Ballardvale Street, Wilmington, United States
MomentumWins
MomentumWins Jun. 20 at 5:47 PM
$CRL 250 breach needs some mojo… it got it now
0 · Reply
JarvisFlow
JarvisFlow Jun. 18 at 10:00 AM
Redburn Atlantic updates rating for Charles River ( $CRL ) to Neutral, target set at 171 → 188.
0 · Reply
swingingtech
swingingtech Jun. 17 at 7:13 PM
$CRL $ALGN $ENPH $FSLR https://wallstreetwaves.com/tuesdays-market-weakness-declines-in-healthcare-technology-and-communications-sectors/
0 · Reply
JarvisFlow
JarvisFlow Jun. 13 at 2:53 PM
Morgan Stanley updates rating for Charles River ( $CRL ) to Equal-Weight, target set at 225 → 220.
0 · Reply
FinJay
FinJay Jun. 6 at 2:11 AM
$CRL https://youtu.be/yQKMLlDzMzM
0 · Reply
ZacksResearch
ZacksResearch Jun. 2 at 2:55 PM
$CRL extends its Huntington's partnership with CHDI Foundation — is sentiment shifting? 🤔 Following the news, shares of Charles River rose 1.1% as the collaboration is set to reach its 20th anniversary in 2025, fueling market optimism. CRL's earnings yield of 7.09% also shines against the industry’s 4.02% yield. See why this extension could boost CRL's outlook 👉 https://www.zacks.com/commentary/2480029/charles-river-stock-may-gain-from-extended-chdi-research-deal-on-hd?cid=sm-stocktwits-2-2480029-body&ADID=SYND_STOCKTWITS_TWEET_2_2480029_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 2 at 11:15 AM
$CRL expands global reach with extended CHDI deal! The extended partnership with the CHDI Foundation promises deeper integration and global flexibility in Huntington's drug discovery. See why this could lift the stock 👉 https://www.zacks.com/stock/news/2480029/charles-river-stock-may-gain-from-extended-chdi-research-deal-on-hd?cid=sm-stocktwits-2-2480029-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2480029_TEASER
0 · Reply
FinJay
FinJay May. 26 at 3:48 AM
$CRL https://youtu.be/yQKMLlDzMzM
0 · Reply
JarvisFlow
JarvisFlow May. 23 at 12:00 PM
Redburn Atlantic has adjusted their stance on Charles River ( $CRL ), setting the rating to Buy with a target price of 188 → 182.
0 · Reply
Estimize
Estimize May. 19 at 1:03 PM
Wall St is expecting 2.50 EPS for $CRL Q2 [Reporting 07/30 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont
0 · Reply
Latest News on CRL
Charles River Introduces Global Biotech Incubator Program

Dec 5, 2024, 8:00 AM EST - 7 months ago

Charles River Introduces Global Biotech Incubator Program


Charles River Laboratories Announces Third-Quarter 2024 Results

Nov 6, 2024, 7:00 AM EST - 8 months ago

Charles River Laboratories Announces Third-Quarter 2024 Results


MomentumWins
MomentumWins Jun. 20 at 5:47 PM
$CRL 250 breach needs some mojo… it got it now
0 · Reply
JarvisFlow
JarvisFlow Jun. 18 at 10:00 AM
Redburn Atlantic updates rating for Charles River ( $CRL ) to Neutral, target set at 171 → 188.
0 · Reply
swingingtech
swingingtech Jun. 17 at 7:13 PM
$CRL $ALGN $ENPH $FSLR https://wallstreetwaves.com/tuesdays-market-weakness-declines-in-healthcare-technology-and-communications-sectors/
0 · Reply
JarvisFlow
JarvisFlow Jun. 13 at 2:53 PM
Morgan Stanley updates rating for Charles River ( $CRL ) to Equal-Weight, target set at 225 → 220.
0 · Reply
FinJay
FinJay Jun. 6 at 2:11 AM
$CRL https://youtu.be/yQKMLlDzMzM
0 · Reply
ZacksResearch
ZacksResearch Jun. 2 at 2:55 PM
$CRL extends its Huntington's partnership with CHDI Foundation — is sentiment shifting? 🤔 Following the news, shares of Charles River rose 1.1% as the collaboration is set to reach its 20th anniversary in 2025, fueling market optimism. CRL's earnings yield of 7.09% also shines against the industry’s 4.02% yield. See why this extension could boost CRL's outlook 👉 https://www.zacks.com/commentary/2480029/charles-river-stock-may-gain-from-extended-chdi-research-deal-on-hd?cid=sm-stocktwits-2-2480029-body&ADID=SYND_STOCKTWITS_TWEET_2_2480029_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 2 at 11:15 AM
$CRL expands global reach with extended CHDI deal! The extended partnership with the CHDI Foundation promises deeper integration and global flexibility in Huntington's drug discovery. See why this could lift the stock 👉 https://www.zacks.com/stock/news/2480029/charles-river-stock-may-gain-from-extended-chdi-research-deal-on-hd?cid=sm-stocktwits-2-2480029-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2480029_TEASER
0 · Reply
FinJay
FinJay May. 26 at 3:48 AM
$CRL https://youtu.be/yQKMLlDzMzM
0 · Reply
JarvisFlow
JarvisFlow May. 23 at 12:00 PM
Redburn Atlantic has adjusted their stance on Charles River ( $CRL ), setting the rating to Buy with a target price of 188 → 182.
0 · Reply
Estimize
Estimize May. 19 at 1:03 PM
Wall St is expecting 2.50 EPS for $CRL Q2 [Reporting 07/30 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont
0 · Reply
Armonica423
Armonica423 May. 10 at 10:00 PM
$CRL Big exposure for CYDY at 3 oncology conferences this next week, do your dd research
0 · Reply
TheDayTradingAcademy
TheDayTradingAcademy May. 8 at 2:44 PM
The U.S. pharmaceutical company $CRL soared +18.68% on Wednesday at $136.97 & another 3% late morning Thursday at $141.10, after lifting its full-year earnings guidance. Charles River now anticipates its adjusted earnings will range from $9.30 to $9.80 per share, compared to its earlier call for $9.10 to $9.60 a share. The stock is up +41.13% in the past month, but still down -23.59% in 2025 & -38.69% y/y, with a market cap of $6.73B.
0 · Reply
JarvisFlow
JarvisFlow May. 8 at 1:00 PM
Baird has updated their rating for Charles River ( $CRL ) to Neutral with a price target of 140.
0 · Reply
KabilSamir
KabilSamir May. 8 at 10:18 AM
0 · Reply
ivychand
ivychand May. 7 at 5:32 PM
$CRL Recently stumbled across an app called stockburger.app — wasn’t expecting much, but gave it a shot. Here’s what stood out so far: ✅ Early alerts on meme stock momentum — pulls from Reddit, Twitter, Discord, etc. ✅ Spikes in attention — flags tickers that are suddenly trending ✅ AI filtering — cuts out junk and focuses on meaningful chatter ✅ Community strength metrics — shows where the hype is coming from ✅ Custom filters — track keywords, sectors, or specific tickers Honestly? Looks promising if you’re into pre-market movers or momentum trades. Been surprisingly useful for spotting action before it hits scanners. Just sharing some personal observations from the past couple days — got an alert, and shortly after, the price took off hard. Pretty impressive follow-through
0 · Reply
damorphius
damorphius May. 7 at 2:08 PM
$CRL Summary: Bullish Thesis 📌 Why Bulls Like CRL: Strong recovery potential after an overdone selloff Industry leadership in essential R&D services Raised full-year guidance and positive margin outlook Undervalued on historical P/E and intrinsic value Optionality from activist involvement and strategic review 🎯 Long-Term Price Target: $175 (12–18 months) 🎯 Realistic Short-Term Target: $150–160 (3–6 months)
0 · Reply
damorphius
damorphius May. 7 at 2:08 PM
$CRL Institutional Confidence High insider and institutional ownership indicates long-term belief in fundamentals. Recent activist involvement (Elliott Investment Management) could unlock shareholder value through business optimization or asset sales.
0 · Reply
damorphius
damorphius May. 7 at 2:07 PM
$CRL Secular Tailwinds Global R&D spending is expected to rebound in late 2025, aided by AI-driven drug discovery and expanding biologics research. CRL's early-stage services are mission-critical to biotech, making it a long-term winner regardless of near-term pharma slowdowns.
0 · Reply
damorphius
damorphius May. 7 at 2:07 PM
$CRL Valuation Discount After Selloff CRL is down ~37% YTD and recently rebounded +18% on earnings news. Current Price (May 7): $136 Forward P/E: ~13.2x vs. 5-year average of ~19x → suggests undervaluation.
0 · Reply
damorphius
damorphius May. 7 at 2:07 PM
$CRL Earnings Stability & Strategic Adjustments Q1 2025 revenue: $984.2M (down 2.7% YoY) but beat analyst expectations. Adjusted EPS: $2.27 vs. $2.05 consensus. Despite lower GAAP income, adjusted earnings outperformed, reflecting effective cost control. The company raised FY2025 EPS guidance to $9.90–$10.40 (from $9.70–$10.20), showing management confidence.
0 · Reply
damorphius
damorphius May. 7 at 2:07 PM
$CRL Strong Market Position in Drug Development Services Charles River is a global leader in outsourced preclinical and clinical laboratory services, which are essential for drug discovery and safety testing. Their diverse client base includes major pharmaceutical and biotech firms, academic institutions, and government agencies—providing revenue stability.
0 · Reply
TulipmaniaJHH
TulipmaniaJHH May. 7 at 1:31 PM
$CRL gonna get smacked in Q2 / Q3 lol, I hope not but it’s inevitable
0 · Reply